Role of Estrogens and Their Receptors in Adhesion and Invasiveness of Breast Cancer Cells

  • Marie Maynadier
  • Philippe Nirdé
  • Jean-Marie Ramirez
  • Anne Marie Cathiard
  • Nadine Platet
  • Monique Chambon
  • Marcel Garcia
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)


Estrogen receptors (ERs) are overexpressed in human breast cancers (BCs) and associated with differentiated tumors and with a more favorable prognosis. Paradoxically, ERs mediate the mitogenic action of estrogens in human BC cells and the efficacy of antiestrogens in adjuvant therapy of primary tumors. The exact mechanism underlying the ER protection against cancer progression to metastasis remains to be investigated. Herein, we show that ERs decrease invasiveness of BC cells. Detailed studies revealed that the unliganded and the E2-activated ERs decrease cancer cell invasion in vitro through two distinct mechanisms. In the presence of ligand, ERα inhibits invasion through a mechanism requiring the functional ERα domains involved in the transcriptional activation of target genes. Moreover, using different approaches, we found that cell-cell contacts were markedly increased by 17β-estradiol (E2) treatment and decreased by the pure antiestrogen, ICI182,780. This cell-cell adhesion was associated with an increase of the major intercellular junctions, desmosomes. Conversely, in the absence of ligand, ERα also inhibits invasion through a distinct mechanism involving protein-protein interaction with the region of the first zinc finger of ERα. The relationship of these data with clinical studies and their potential therapeutic consequences will be discussed.


Breast Cancer Estrogen Receptor Cancer Cell Invasion Normal Mammary Cell Pure Antiestrogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pike MC, Krailo MD, Henderson BE, et al. (1983) Hormonal risk factors, breast tissue age and the age-incidence of breast cancer. Nature 303:767–770.PubMedCrossRefGoogle Scholar
  2. 2.
    Mangelsdorf DJ, Thummel C, Beato M, et al. (1996) The nuclear receptor superfamily: the second decade. Cell 86:835–839.CrossRefGoogle Scholar
  3. 3.
    Gustafsson JA (1999) Estrogen receptor ß – a new dimension in estrogen mechanism of action. J Endocrinol 163:379–383.PubMedCrossRefGoogle Scholar
  4. 4.
    McGuire WL (1978) Hormone receptor: their role in predicting prognosis and response to endocrine therapy. Semi Oncol 5:2428–2433.Google Scholar
  5. 5.
    Fisher B, Jeong JH, Dignam J, et al. (2001) Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 30:62–66.PubMedGoogle Scholar
  6. 6.
    Fuqua SA, Schiff R, Parra I, et al. (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63:2434–2439.PubMedGoogle Scholar
  7. 7.
    Rochefort H, Platet N, Hayashido Y, et al. (1998) Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J Steroid Biochem Molec Biol 65:163–168.PubMedCrossRefGoogle Scholar
  8. 8.
    Garcia M, Rochefort H (2000) Estrogen receptor targeted therapies of breast cancer. Cur Opin Oncol Endocr Metab Invest Drugs 2:60–67.Google Scholar
  9. 9.
    Garcia, M, Derocq D, Freiss G, et al. (1992) Activation of estrogen receptor into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89:1538–11542.Google Scholar
  10. 10.
    Long BJ, Rose DP (1996) Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER. Cancer Lett 99:209–215.PubMedCrossRefGoogle Scholar
  11. 11.
    Platet N, Cunat S, Chalbos D, et al. (2000) Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 14:999–1009.PubMedCrossRefGoogle Scholar
  12. 12.
    Laios I, Journe F, Laurent G, et al. (2003) Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol 87:207–221.PubMedCrossRefGoogle Scholar
  13. 13.
    Green S, Kumar V, Theulaz I, et al. (1988) The N-terminal DNA-binding ‘zinc finger’ of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO J 7:3037–44.PubMedGoogle Scholar
  14. 14.
    Platet N, Prevostel C, Derocq D, et al. (1998) Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer 75:750–756.PubMedCrossRefGoogle Scholar
  15. 15.
    Thompson EW, Paik S, Brünner N, et al. (1992) Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150:534–544.PubMedCrossRefGoogle Scholar
  16. 16.
    Marsden J, Backs NPM (1996) Hormone replacement therapy and breast cancer. Endocr Relat Cancer 3:81–97.CrossRefGoogle Scholar
  17. 17.
    Collaborative group on hormonal factors in breast cancer (1997) Lancet 350:1047–1059.CrossRefGoogle Scholar
  18. 18.
    Li CI, Malone KE, Weiss NS, et al. (2001) Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 13:1008–1013.CrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Marie Maynadier
  • Philippe Nirdé
    • 1
  • Jean-Marie Ramirez
  • Anne Marie Cathiard
  • Nadine Platet
  • Monique Chambon
    • 1
  • Marcel Garcia
    • 1
  1. 1.Inserm Unit 540MontpellierFrance

Personalised recommendations